Saint Luke's News

Team Highlight: Cath Lab and EP Lab Nurses at Saint Luke’s Mid America Heart Institute
The Saint Luke's Cath Lab and EP Lab teams play key roles in saving and improving the lives of many in cardiac emergencies. Nurses Kim Filla and Holly Steinshouer explain what their teams do every day.
Saint Luke’s News: Trials show medications for ovarian cancer dramatically reduce chance of recurrence in wide range of patients
Two recent trials are giving new hope to more patients with ovarian cancer. Dr. Michelle Rowland talks about the exciting advancement and what women can do to help catch ovarian cancer early.
Saint Luke's News: Doctors strongly discourage vaping as multiple deaths reported in Kansas and Missouri among illness outbreak
Federal health officials are investigating an outbreak of serious lung injuries and deaths related to e-cigarettes and vaping products. Dr. Vincent Lem explains how anyone who vapes is susceptible.
FAME: Plaza Art Fair cooking segment with Seasons 52
Lucas Schubert, Nutritional Coordinator with Saint Luke's Mid America Heart Institute and the Food As Medicine Everyday (FAME) program, shares how to make two tasty recipes at Seasons 52 for the 2019 Plaza Art Fair.
Wright Memorial Physicians’ Group welcomes Khannah Smith, MD, to the medical team
Wright Memorial Physicians’ Group in Trenton is pleased to welcome internal medicine physician, Khannah (pronounced Hannah) Smith, MD, to the medical team.
Wright Memorial Hospital Launches Nurse Navigator Oncology Program
Wright Memorial Hospital recently launched a new program that will provide an oncology nurse navigator dedicated to easing the physical, spiritual, emotional, and financial hardships of living with and beyond cancer.
Saint Luke’s leads first of its kind trial to help patients with heart failure – DEFINE-HF
DEFINE-HF was not only the first multi-center randomized placebo-controlled clinical trial that Saint Luke’s developed, coordinated, and implemented in its entirety, but the first significant effort to look at what effect dapagliflozin, a drug initially created for the treatment of diabetes, was going to have in patients who also have heart failure.